RxDoctor Payments DataLook up a doctor →

Barry Kaufman, MD

Gastroenterology · Egg Harbor Township, NJNPI 1154499085

Payments from drug & device makers

$595,054in general payments, 2019–2025

Across 1,100 payments — averaging $540.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$452K
  • Pfizer$36K
  • E.r. Squibb & Sons, L.L.C.$34K
  • Janssen Scientific Affairs, LLC$33K
  • Boehringer Ingelheim International GmbH$10K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$9K
  • plus $21K from 40 others

What the payments were for

  • Consulting fees$10,3287%
  • Speaking & faculty fees$103,81866%
  • Travel & lodging$27,51218%
  • Food & beverage$15,06110%
  • Education$820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$595,054 in reported general payments places this provider in the 95th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$78,974
Medicare patients
357
Services billed
556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$445,941
Skyrizi On-BodyRisankizumab-Rzaa15$316,216
EntyvioVedolizumab31$261,926
RinvoqUpadacitinib14$85,387
XifaxanRifaximin20$62,675
LinzessLinaclotide28$25,513
Dexlansoprazole DrDexlansoprazole46$24,933
Mesalamine24$17,691
Omeprazole313$5,905
Esomeprazole Magnesium95$3,970
Colesevelam Hcl14$2,196
Famotidine51$1,287
Pantoprazole Sodium77$1,244
Lansoprazole14$633
Ondansetron OdtOndansetron12$246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$932$445,94117 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$8,033$261,92631 claims
AbbVieRinvoq, Linzess$451,520$110,90042 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$816$62,67520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Egg Harbor Township

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →